To test this possibility, we compared the list of splicing events common across all stages of prostate cancer (A∩B∩C∩D) and list of splicing events induced by either pharmacological and genomic inhibition of AR in LNCaP and MDA-PCa-2b cells (Supplementary Fig. 7, A–C). The gene discussed is AR; the disease is Familial prostate cancer.